All In Biotech

Drug Trial Radar · NCT00000991

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection

Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Not stated

Primary completion

Not stated

Study completion Apr 1994

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3. All persons completing at least 8 weeks of therapy on 081 will be offered the opportunity to participate in the nested study (ACTG 981) of systemic antifungal therapy (fluconazole) versus local therapy (Clotrimazole) for the prevention of serious fungal disease. Persons with HIV disease who are receiving AZT are at risk for PCP, toxoplasmosis, bacterial pneumonia, and other serious infections. It is therefore important to find drugs that can be given along with AZT to control these infections. Aerosolized pentamidine (PEN) has been shown to be useful in preventing PCP and is expected to lower the 2-year risk of PCP. Both sulfamethoxazole/trimethoprim (SMX/TMP) and dapsone probably also provide effective preventive treatment against PCP, and both may be useful in preventing toxoplasmosis and extrapulmonary pneumocystosis.

Conditions

  • Pneumonia, Pneumocystis Carinii
  • HIV Infections

Interventions

  • Pentamidine isethionateDrug

  • Sulfamethoxazole-TrimethoprimDrug

  • DapsoneDrug

  • ZidovudineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • USC CRS

    Los Angeles, California

  • Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.

    Oakland, California

  • Ucsd, Avrc Crs

    San Diego, California

  • Univ. of Miami AIDS CRS

    Miami, Florida

  • Chicago Children's CRS

    Chicago, Illinois

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Johns Hopkins Adult AIDS CRS

    Baltimore, Maryland

  • Massachusetts General Hospital ACTG CRS

    Boston, Massachusetts

  • Beth Israel Deaconess - East Campus A0102 CRS

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • University of Minnesota, ACTU

    Minneapolis, Minnesota

  • Washington U CRS

    St Louis, Missouri

  • SUNY - Buffalo, Erie County Medical Ctr.

    Buffalo, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • Unc Aids Crs

    Chapel Hill, North Carolina

  • Duke Univ. Med. Ctr. Adult CRS

    Durham, North Carolina

  • Case CRS

    Cleveland, Ohio

  • The Ohio State Univ. AIDS CRS

    Columbus, Ohio

  • Pitt CRS

    Pittsburgh, Pennsylvania

  • University of Washington AIDS CRS

    Seattle, Washington

  • Mbeya Med. Research Program, Mbeya Referral Hosp. CRS

    Mbeya, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.